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INTRODUCTION: Several aspects of gastroesophageal reflux disease (GERD) have been studied, but the frequency of comor-
bidities is not yet fully understood. 
OBJECTIVES: To study the prevalence of GERD comorbidities in a tertiary care hospital.
METHODS: We prospectively studied 670 consecutive adult patients from the outpatient department of our facility. A diagnosis 
was established using clinical, endoscopic and/or pHmetry-related findings. Each patient’s medical file was reviewed with respect 
to the presence of other medical conditions and diagnoses. 
RESULTS: Of the 670 patients, 459 (68.6%) were female, and the mean age was 55.94 (17-80 years). We registered 316 patients 
(47.1%) with the erosive form of GERD and 354 patients (52.9%) with the non-erosive form. A total of 1,664 instances of comor-
bidities were recorded in 586 patients (87.5%), with the most common being arterial hypertension (21%), hypercholesterolemia 
(9%), obesity (9%), type II diabetes mellitus (5%) and depression (4%). Two or more comorbidities were present in 437 individu-
als (64.8%). The occurrence of comorbidities increased with age and was higher in patients with the non-erosive form of GERD. 
CONCLUSIONS: In a tertiary referral population, comorbidities were very common, and these may have worsened the already 
impaired health-related quality of life of these patients. Clinicians caring for GERD patients in this setting must be aware of the 
likelihood and nature of comorbid disorders and their impact on disease presentation and patient management.
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INTRODUCTION
Gastroesophageal  reflux  disease  (GERD)  is  a 
very common and costly disorder. The majority of 
epidemiological studies have based their prevalence 
estimates on symptoms of heartburn and acid regurgitation, 
the cardinal symptoms of GERD, which have been reported 
to occur on a daily basis by 10% of the adult population in 
the United States1 and 7.3% in Brazil.2
Many aspects of the physiopathology, diagnosis and 
treatment of GERD have been reviewed in detail3-5 and 
are relatively well known. Despite the advances in our 
understanding of the mechanisms of this disease, however, 
some important areas still remain incompletely understood, 
such as the prevalence and nature of comorbid disorders.
The objective of this study was to investigate the point 
prevalence of comorbid disorders in GERD and to assess 
their connection with age, gender, smoking habits and the 
clinical presentation of the disease (i.e., non-erosive reflux 
disease (NERD) vs. erosive GERD) in São Paulo, Brazil.
MATERIALS AND METHODS
A total of 670 prospective, consecutive adult patients 
with GERD who had been referred to the outpatient clinic of 786
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the Esophageal Diseases Sector of the Hospital das Clínicas 
of the University of São Paulo, a tertiary medical referral 
center, between September 2006 and December 2007 were 
enrolled.
The diagnosis of GERD was established on the basis 
of the cardinal symptoms, namely heartburn and acid 
regurgitation, occurring two or more times a week, with or 
without other symptoms, for at least 8 weeks.6,9 
The Los Angeles endoscopic grading system for 
esophagitis severity8 was used for the endoscopic diagnosis 
of erosive esophagitis. NERD was diagnosed by the presence 
of troublesome reflux-associated symptoms and the absence 
of mucosal breaks at endoscopy7, in addition to 24-hour 
ambulatory pH-metry in the context of acid reflux.10 
During the medical consultation, an extensive review 
of the patient’s medical file was carried out, including 
documentation of all previous medical consultations 
involving different hospital services. During this review, all 
established diagnoses and prescribed treatments, as well as 
the results of any related investigations were recorded. 
All comorbidities (CMs) were diagnosed according 
to established criteria.11,12 All data were recorded in the 
patient’s report forms, which also included detailed 
information regarding the diagnosis and treatment of GERD. 
The results were stored in a database.
Patients were excluded if they had previously undergone 
gastrointestinal surgery, or if they suffered from Barrett´s 
esophagus or other complications as evidenced during upper 
endoscopy. Women were required to be non-pregnant, non-
lactating and on a medically acceptable form of birth control.
The study was approved by the Institutional Ethics 
Committee of the Hospital das Clinicas of the University of 
São Paulo School of Medicine (Cappesq). 
A descriptive analysis was used to document the 
demographic and clinical data related to the patient cohort. 
To test for age-related statistical differences between the 
genders, a Student’s t-test was used. Comparisons of the 
proportions among groups with regard to gender were 
evaluated using a binomial test, with a null hypothesis 
of 50% for each sex. A p value of <0.05 was considered 
statistically significant. Statistical software R version 2.6.2 
for windows (R Foundation for Statistical Computing, USA) 
was used for data processing and analyses.
RESULTS
The duration of GERD history among the 670 patients 
ranged from 8 weeks to 20 years (mean: 9.2 years). In total, 
we studied 211 (31.4%) males and 459 (68.6%) females; of 
these, 586 (87.5%) had documented comorbidities, and 84 
(12.5%) did not.
Of the patients with CMs, 423 (72.1%) were female 
and 163 (27.9%) were male (p<0.0001). Of those without 
CMs, 48 (57.2%) were male and 36 (42.8%) were female 
(p=0.2301) (Table 1). 
At endoscopy, 316 patients presented erosive esophagitis 
(47.1%) and 354 (52.9%) did not. 
Of the 316 patients with erosive esophagitis, 202 (63.9%) 
were female and 114 (36.1%) were male (p<0.0001). Of the 
354 patients with non-erosive reflux disease, 257 (72.6%) 
were female and 97 (27.4%) were male (p<0.0001) (Table 2).
Ages in the studied population ranged from 18 to 80 
years, with a mean of 55.94 years (CI 95%: 54.93; 56.96). 
The mean ages for males and females were 55.81 (CI 
95%:53.75; 57.87) and 56.0 (CI 95%:54.87; 57.12) years, 
respectively. There were no statistical differences between 
genders with respect to age (p=0.8770).
Table 1 - Presence or absence of comorbidities in relation to 
gender in GERD patients 
GERD Females Males P
With CMs
586 (87.5%)
423
(72.18%)
163
(27.81%)
<0.0001
Without CMs
84 (12.5%)
36
(42.86%)
48
(57.14%)
0.2301
Total 
670 
459
(68.6%)
211
(31.4%)
<0.0001
Table 2 - Erosive GERD and NERD in relation to gender
Female  Male  P
CMs
present
CMs
absent
Total CMs
present
CMs
absent
Total
Erosive GERD
316 (47.1%) 
188
(93%)
14
(7%)
202
(100%)
94
(82%)
20
(18%)
114
(100%)
<0.0001
NERD
354 (52.9%) 
235
(91%)
22
(9%)
257
(100%)
69
(71%)
28
(29%)
97
(100%)
<0.0001
Total
(670)
423 36 459 163 48 211 <0.0001787
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A total of 1,664 instances of comorbidities among 586 
patients (87.5%) were identified. The ten most common 
comorbidities, which accounted for 1,099 occurrences 
(66.0% of the total), corresponding to 509 patients (75.9% 
of the total), are shown in Table 3.
A higher frequency of comorbidities occurred in the age 
range of 61 to 70 years, with 354 instances (21.2% of the 
total occurrences), and in the age range of 51 to 60 years, 
with 336 instances (20.1% of the total occurrences). The 
occurrence rate of the ten most prevalent CMs according to 
age range is shown in Table 4. 
The numbers of patients by age range were: 18-20 years, 
1; 21-30 years, 22(3%); 31-40 years, 59 (9%); 41-50 years, 
141 (21%); 51-60 years, 189 (28%); 61-70 years, 163 (24%); 
and 71-80 years, 93 (14%). 
As seen from Table 5, the occurrence of CMs was 
significantly higher in patients with NERD (p=0.0014). 
Furthermore, in patients with erosive disease most 
comorbidities were associated with patients suffering from 
milder grades of esophagitis (i.e., Los Angeles grades A 
and B) (p<0.0001). Comorbidities among patients with 
the aforementioned grades accounted for 92.14% (CI95%: 
89.32%; 94.28%) of the total number of comorbidities 
associated with erosive GERD.
DISCUSSION
To our knowledge, very few original papers have 
analyzed the prevalence of CMs in GERD, an acid-related 
disorder that develops when the reflux of gastric contents 
induces troublesome symptoms, with or without esophageal 
mucosal damage and/or complications7. GERD may present 
with a broad spectrum of symptoms, but the cardinal 
manifestations are heartburn and acid regurgitation. In our 
study, we considered these adequate for the preliminary 
diagnosis of GERD. Complications of the disease, 
including Barrett’s esoophagus, stenosis and ulcers, are 
often associated with other clinical manifestations and, as 
such, were excluded from the present study. As expected, 
a majority of the patients (53%) presented with the non-
erosive form of the disease.13 
Although this study was conducted in a tertiary care 
hospital where CMs are expected, the occurrence rate 
of more of 80% is quite impressive. Several factors 
may contribute to the high prevalence of comorbidities 
Table 3 - The ten most prevalent comorbidities in GERD 
patients
Comorbidities Occurrences % total Comorbidities 
Arterial Hypertension  344 20.6
Hypercholesterolemia 158 9.5
Obesity 158 9.5
Type II Diabetes mel-
litus 
82 4.9
Depression 74 4.4
Arthritis 62 3.7
Osteoporosis 59 3.5
Asthma 56 3.3
Constipation 54 3.2
Allergic Rhinitis  52 3.1
Table 4 - Most prevalent comorbidities in GERD sufferers according to age range 
Comorbidity
 
Age range
18-20 21-30 31-40 41-50 51-60 61-70 71-80 Total 
occurrences 
(% total)
Hypertension __ 1 9 (15%) 51 (36%) 98 (52%) 115 (71%) 70 (75%) 344 (20.6%)
Hypercholesterolemia - 2 (9%) 5 (8%) 23 (16%) 44 (23%) 58 (36%) 26 (28%) 158 (9.5%)
Obesity - 4 (18%) 11 (19%) 35 (25%)  51 (27%) 42 (26%) 15 (16%) 158 (9.5%)
Type II diabetes mellitus  - 0 1 13 (9%) 20 (11%) 26 (16%) 22 (24%) 82 (4.9%)
Depression - 1 4 (7%) 18 (13%) 26 (14%) 15 (9%) 10 (11%) 74 (4.4%)
Arthritis - 1 2 (3%) 6 (4%) 20 (11%) 17 (10%) 16 (17%) 62 (3.7%)
Osteoporosis - - - 2 (1%) 13 (7%) 28 (17%) 16 (17%) 59 (3.5%)
Asthma 1 1 3 (5%) 18 (13%) 14 (7%) 14 (9%) 5 (5%) 56 (3.3%)
Constipation - 2 (9%) 7 (12%) 13 (9%) 11 (6%) 13 (8%) 8 (9%) 54 (3.2%)
Allergic Rhinitis  - 1 8 (14%) 11 (8%) 20 (11%) 8 (5%) 4 (4%) 52 (3.1%)
Total occurrences 1 13 50 190 317 336 192 1099
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observed in our series, including the fact that the study was 
carried out in a tertiary care hospital that receives patient 
referrals from primary and secondary care hospitals, as 
well as from healthcare centers in the city of São Paulo. 
As a consequence, our sample is probably biased towards 
individuals with more symptomatic, complicated and non-
responsive disease profiles. Furthermore, since this hospital 
treats a full range of medical disorders – again, on a referral 
basis – individuals with other medical conditions are more 
likely to be admitted. We emphasize, however, that our 
goal was not to define the relative prevalence of comorbid 
disorders among GERD patients and control subjects in the 
community, but rather to document the range of conditions 
that may accompany GERD in a referral hospital population. 
We also wished to identify factors that may contribute to 
their occurrence. This is not an epidemiological study, and 
we do not mean to imply that it is such a study.
In reality, this study is a transverse, point-prevalence 
study in a tertiary referral population. There is some 
evidence, however, to suggest that the distribution and 
prevalence of comorbidities are representative of the general 
population. For instance, systemic arterial hypertension, 
which is known to affect 20 to 30% of the general 
population,14,15 was present in this series in 29% of all 
patients with NERD and in 20.6% of the entire GERD 
population studied. The same is true for the prevalence of 
type II diabetes mellitus, which is present in around 8% of 
the Brazilian population16 and in 6% and 4.9% (NERD and 
GERD, respectively) of the present cohort. 
Obesity, which is a risk factor for GERD, has recently 
reached epidemic proportions, with a prevalence of 
30% worldwide.17,18 Obesity was observed in 9.5% of 
our patients, and a similar percentage suffered from 
hypercholesterolemia. It is noteworthy that, together 
with diabetes and arterial hypertension, obesity and 
hypercholesterolemia constitute important risk factors for 
coronary heart disease19, the symptoms of which may mimic 
GERD and contribute to considerable diagnostic confusion. 
It is also important to point out that these diseases were 
the four most prevalent comorbidities in our study, both in 
isolation and in association with others. Although we do 
not have any data regarding serum triglyceride levels or 
measurements of abdominal circumference, it is possible 
that many of our patients were suffering from metabolic 
syndrome.20 
Somewhat surprisingly, comorbidities were more 
prevalent in patients with NERD than in those with erosive 
disease, with a notable trend towards fewer comorbidities 
as the grade of esophagitis increased. Although NERD 
should be regarded as a real component within the GERD 
spectrum,21 it behaves differently with regard to the response 
to treatment with proton-pump inhibitors22 and demonstrates 
a more homogeneous acid distribution along the esophagus.23 
Our findings provide further evidence for NERD being a 
somewhat distinctive subgroup of GERD.
Depression affects an average of 16% of the general 
population at some point during adult life24 and was present 
in 4.4% of our patients, which was somewhat lower than the 
expected prevalence. This may be due to the nature of our 
protocol, a point-prevalence study, which does not accurately 
capture past or future episodes. Additionally, despite its 
clinical importance, depression is still under-diagnosed 
(which may also have been a problem with the present 
series) due to several factors, including the minimization 
of symptoms and the stigma related to psychiatric disease. 
It has been shown that the health-related quality of 
Table 5 - Ten most frequent comorbidities according to GERD endoscopic Los Angeles grade and NERD
Comorbidities GERD
NERD LA - Grade A LA - grade B LA - grade C LA - grade D Number of Occurrences 
(% of total)
Hypertension 193 (29%) 101 (15%) 39 (6%) 9 (1%) 2 344 (20.6%)
Hypercholesterolemia 84 (13%) 47 (7%) 22 (3%) 5 (1%) - 158 (9.5%)
Obesity 81 (12%) 42 (6%) 25 (4%) 9 (1%) 1 158 (9.5%)
Type II diabetes mellitus  43 (6%) 28 (4%) 7 (1%) 3 1 82 (4.9%)
Depression 40 (6%) 23 (3%) 10 (1%) 1 - 74 (4.4%)
Arthritis  38 (6%) 13 (2%) 9 (1%) 2 - 62 (3.7%)
Osteoporosis 36 (5%) 16 (2%) 5 (!%) 2 - 59 (3.5%)
Asthma  29 (4%) 17 (3%) 7 (1%) 2 1 56 (3.3%)
Constipation 32 (5%) 18 (3%) 4 (1%) - - 54 (3.2%)
Allergic Rhinitis  27 (4%) 15 (2%) 9 (1%) 1 - 52 (3.1%)
Number of occurrences (% of total) 603 (53.0%)  320 (19.2%) 137 (8.2%) 34 (2.0%) 5 (0.3%) 1,099789
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life (HRQoL) of patients with GERD may be seriously 
impaired.25,26 It is possible that the presence of comorbidities, 
in addition to the esophageal disease itself, also contributes 
to impaired quality of life in these cases. Instead of 
simply targeting the esophageal symptoms in such cases, 
a more comprehensive approach is required, which also 
encompasses the comorbid conditions. 
Finally, an appreciation of the prevalence and nature 
of comorbidities should assist clinicians in identifying 
better therapeutic approaches for these patients. This 
should include consideration of the possible interactions 
with drugs used in the treatment of the comorbidities 
and of GERD, including calcium channel blockers, beta-
adrenergic antagonists, non-steroidal anti-inflammatory 
agents (NSAID’s), anti-diabetic agents, sibutramine, tricyclic 
antidepressants, etc. 
In conclusion, in a hospital with a tertiary referral 
population, comorbidities of GERD were very common. 
Such conditions may contribute to the already impaired 
health-related quality of life of these patients. Our findings 
must be studied in other settings before any generalizations 
can be made, but clinicians caring for GERD patients in 
this setting must be aware of the likelihood and nature of 
comorbid disorders and their impact on disease presentation 
and patient management.
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